The ongoing 201 trial evaluating Risvodetinib in untreated Parkinson's disease is a significant event for Inhibikase Therapeutics. The results of this trial could potentially impact the company's stock, either positively if the results are favorable, or negatively if the results are not. However, as the results are not yet known, the impact on the stock is currently neutral.